Sep 18, 2026, 05:45 UTC
Sandoz announced a licensing, development, manufacturing and commercialisation agreement with mAbxience for a proposed emicizumab biosimilar, with Sandoz holding exclusive global commercialisation rights excluding Argentina, Uruguay and Paraguay.
Sep 16, 2026, 00:46 UTC
On September 15, US-listed ADRs of Japanese companies traded with a slight selling bias, with Chugai Pharmaceutical and Takeda Pharmaceutical among the decliners, while Chicago Nikkei 225 futures settled at 63,405 yen, 285 yen above the Osaka daytime level.
Source:Sep 15, 2026, 10:09 UTC
The Pharmaceutical and Cosmetics Industry Labor Union Federation (Yakusho Rengo) plans to formally join Rengo (the Japanese Trade Union Confederation) by October 2027, its chairman Hideo Matsuo said at a press conference on September 15, 2026.
Source:Sep 10, 2026, 02:31 UTC
Three researchers from Chugai Pharmaceutical, including former senior fellow Arihiro Hattori, were awarded the 2026 Lasker Award in clinical medicine for developing Hemlibra, a drug that transformed hemophilia treatment.
Source:Sep 2, 2026, 09:17 UTC
Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.
Source:Aug 28, 2026, 09:39 UTC
Chugai Pharmaceutical submitted a manufacturing and marketing approval application to Japan's Ministry of Health, Labour and Welfare for its anti-IL-6 monoclonal antibody 'Vamikibart' for the indication of macular edema associated with non-infectious uveitis.
Source:Aug 18, 2026, 02:38 UTC
Chugai Pharmaceutical and GlaxoSmithKline signed an exclusive license agreement on August 18, 2026, granting GSK global rights to develop, manufacture, and commercialize the dengue antibody drug AID351, with Chugai eligible for royalties and a share of sublicensing revenue.
Source:Aug 5, 2026, 08:25 UTC
Chugai Pharmaceutical has applied to the Ministry of Health, Labour and Welfare for manufacturing and marketing approval of the therapeutic drug "satralizumab" for the prevention of relapse of MOG antibody-associated disease (MOGAD) as the intended indication. If approved, it would be the first insurance-covered therapeutic drug in Japan.
Source:Aug 4, 2026, 04:39 UTC
Chugai Pharmaceutical has signed a partnership agreement with the Japan Basketball Association (JBA) as a "Healthcare Innovation Partner".
Source: